Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labo EuromedisSTU:61R +2.95%68 Forward Dividend Yield % is 0.00% as of Jul. 13, 2026. GuruFocus rates STU:61R with a GF Score™ of 68/100 and a GF Value™ of €4.39 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 66 Medical Distribution companies, Labo Euromedis ranks worse than 1515150% on this metric.
As of today (2026-07-13), the Forward Annual Dividend Yield of Labo Euromedis is 0.00%.
As of today (2026-07-13), the Trailing Annual Dividend Yield of Labo Euromedis is 0.00%.
STU:61R's Forward Dividend Yield % is not ranked *
in the Medical Distribution industry.
Industry Median: 2.8 * Ranked among companies with meaningful Forward Dividend Yield % only.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Labo Euromedis was 8.70% per year. The lowest was 8.70% per year. And the median was 8.70% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Labo Euromedis Forward Dividend Yield % Related Terms
STU:61R vs MCK, CAH, COR: Forward Dividend Yield % Comparison
For the Medical Distribution subindustry, Labo Euromedis's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Forward Dividend Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Labo Euromedis (STU:61R) has a Forward Dividend Yield % of 0.00% as of Jul. 13, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Labo Euromedis and its competitors. According to the industry distribution chart, Labo Euromedis ranks #999999 out of 66 companies in the Medical Distribution industry.
Is Labo Euromedis' Forward Dividend Yield % too high?
Labo Euromedis' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Labo Euromedis ranks #999999 out of 66 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Labo Euromedis has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Forward Dividend Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #999999 out of 66 companies for Forward Dividend Yield %. This places Labo Euromedis in the lower half of its industry. The industry median Forward Dividend Yield % is 2.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Distribution company?
The median Forward Dividend Yield % among Medical Distribution companies is 2.80, based on 66 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median Forward Dividend Yield % is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (STU:61R) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.39, compared to a current price of €4.88 — trading 11.2% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Labo Euromedis' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Labo Euromedis (STU:61R), the current Forward Dividend Yield % is 0.00% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (STU:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.88 is trading 11.2% above its estimated GF Value™ of €4.39.
GuruFocus considers Labo Euromedis to be Modestly Overvalued.
Key valuation signals for STU:61R:
Forward Dividend Yield %: 0.00%
GF Value™: €4.39 vs. price of €4.88 (11.2% above fair value)
No single metric tells the full story. See the STU:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
68GF Score
Get the complete analysis for STU:61R
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:61R has been successfully added to your 
